2Ramesh K. Ramanathan,Chandra P. Belani,Deepti A. Singh,Michael Tanaka,Heinz-Josef Lenz,Yun Yen,Hedy L. Kindler,Syma Iqbal,Jeff Longmate,Philip C. Mack,Georg Lurje,Regina Gandour-Edwards,Janet Dancey,David R. Gandara.A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer[J]. Cancer Chemotherapy and Pharmacology . 2009 (4)
3Santamaria E,Munoz J,Fernandez-Irigoyen J,et al.Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver International . 2007
4Citri A,Yarden Y.EGF-ERBB signalling:towards the systems level. Nature Reviews Molecular Cell Biology . 2006
5Ahsan A,Hiniker SM,Davis MA,et al.Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radio sensitization. Cancer Research . 2009
6Ramalingam S,Belani CP.Recent advances in targeted therapy for non-small cell lung cancer. Expert Opinion on Therapeutic Patents . 2007
7Buckley AE,Burgart LJ,Sahai V,et al.Epidermal growthfactor receptor expression and gene copy number in conventional hepatocellular carcinoma. American Journal of Clinical Pathology . 2008
8Zhu AX,,Stuart K,Blaszkowsky LS,et al.Phase2study of cetuximab in patients with advanced hepatocellular carci-noma. Cancer . 2007
9Gruenwald V,,Wilkens L,Gebel M,et al.A phaseⅡopen-label study of cetuximab in unresectable hepatocellu-lar carcinoma:final results. J Clin Oncol(Meeting Ab-stracts) . 2007
10Laloiupala t iSn.Ranodsm coertudxuicm Oa,be fto arl.tGreeamtmceitnatb oinfe h,eopxa--tocellular carcinoma(HCC):results of the phaseⅡstudy ERGO. Journal of Clinical Oncology . 2007
二级参考文献15
1Shirakata Y, Komurasaki T, Toyoda H, et al. Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes [J]. J Biol Chem, 2000,275 ( 8 ) : 5748-5753.
2Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme [ J ]. Cancer Res, 2003,63 (20) : 6962-6970.
3Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the v Ⅲ mutation of human epidermal growth factor receptor [J]. Tumour Biol, 2002,23(2) :61-69.
4Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy [J]. Curr Cancer Drug Targets, 2002,2(2):91-102.
5Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion [J]. Cancer Res, 2002,62(12) :3335-3339.
6Luo X, Gong X, Tang CK. Suppression of EGFRv Ⅲ-mediatedproliferation and tumorigenesis of breast cancer cells by ribozyme [J]. Int J Cancer, 2003,104(6) :716-721.
7Lavictoire SJ, Parolin DA, Klimowicz AC, et al. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRv Ⅲ [J]. J Biol Chem, 2003,278(7):5292-5299.
8Okamoto I, Kenyon LC, Emlet DR, et al. Expression of constitutively activated EGFRv Ⅲ in non-small cell lung cancer[J]. Cancer Sci, 2003,94( 1 ) :50-56.
9Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours [J]. Cancer Treat Rev, 2004,30(1):1-17.
10Wikstrand CJ, Reist C J, Archer GE, et al. The class Ⅲ variant of the epidermal growth factor receptor [EGFRv Ⅲ]:characterization and utilization as an immunotherapeutic target[J]. J Neurovirol, 1998,4(2) : 148-158.
